Madison Honey

Ms. Madison Honey

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 September 2024 in Journal of Neurochemistry
Verified
Journal Article
Open access
DGDea Gogishvili
Dea Gogishvili
MHMadison Honey
Madison Honey
IVInge M. W. Verberk
Inge M. W. Verberk
LVLisa Vermunt
Lisa Vermunt
Elly HolElly Hol
Elly Hol
SASanne Abeln
Sanne Abeln
Glial fibrillary acidic protein (GFAP) is a well‐established biomarker of reactive astrogliosis in the central nervous system because of its elevated levels following brain injury and various neurological disorders. The advent of ultra‐sensitive methods for measuring low‐abundant proteins has significantly enhanced our understanding of GFAP levels in the serum or plasma of patients with diverse neurological diseases. Clinical studies have demonstrated that GFAP holds promise both as a diagnostic and prognostic biomarker, including but not limited to individuals with Alzheimer's disease. GFAP exhibits diverse forms and structures, herein referred to as its proteoform complexity, encompassing conformational dynamics, isoforms and post‐translational modifications (PTMs). In this review, we explore how the proteoform complexity of GFAP influences its detection, which may affect the differential diagnostic performance of GFAP in different biological fluids and can provide valuable insights into underlying biological processes. Additionally, proteoforms are often disease‐specific, and our review provides suggestions and highlights areas to focus on for the development of new assays for measuring GFAP, including isoforms, PTMs, discharge mechanisms, breakdown products, higher‐order species and interacting partners. By addressing the knowledge gaps highlighted in this review, we aim to support the clinical translation and interpretation of GFAP in both CSF and blood and the development of reliable, reproducible and specific prognostic and diagnostic tests. To enhance disease pathology comprehension and optimise GFAP as a biomarker, a thorough understanding of detected proteoforms in biofluids is essential. image

6 December 2021 in Cells
Verified
Journal Article
Open access
PDF file
MHMadison Honey
Madison Honey
YJYorrick R.J. Jaspers
Yorrick R.J. Jaspers
MEMarc Engelen
Marc Engelen
SKStephan Kemp
Stephan Kemp
IHIrene C. Huffnagel
Irene C. Huffnagel
X-linked adrenoleukodystrophy (ALD) is an inherited progressive neurometabolic disease caused by mutations in the ABCD1 gene and the accumulation of very long-chain fatty acids in plasma and tissues. Patients present with heterogeneous clinical manifestations which can include adrenal insufficiency, myelopathy, and/or cerebral demyelination. In the absence of a genotype-phenotype correlation, the clinical outcome of an individual cannot be predicted and currently there are no molecular markers available to quantify disease severity. Therefore, there is an unmet clinical need for sensitive biomarkers to monitor and/or predict disease progression and evaluate therapy efficacy. The increasing amount of biological sample repositories (‘biobanking’) as well as the introduction of newborn screening creates a unique opportunity for identification and evaluation of new or existing biomarkers. Here we summarize and review the many studies that have been performed to identify and improve knowledge surrounding candidate molecular biomarkers for ALD. We also highlight several shortcomings of ALD biomarker studies, which often include a limited sample size, no collection of longitudinal data, and no validation of findings in an external cohort. Nonetheless, these studies have generated a list of interesting biomarker candidates and this review aspires to direct future biomarker research.

15 April 2026 in Nature Medicine
Verified
Journal Article
Open access
PDF file
MHMadison Honey
Madison Honey
YHYanaika S. Hok-A-Hin
Yanaika S. Hok-A-Hin
ETElisabeth H. Thijssen
Elisabeth H. Thijssen
KCKatheryn A. Q. Cousins
Katheryn A. Q. Cousins
BWBabette van der Weijden
Babette van der Weijden
CTCharlotte E. Teunissen
Charlotte E. Teunissen
Biomarkers to determine underlying frontotemporal lobar degeneration (FTLD) tau or TAR DNA-binding protein (TDP) pathology during life are needed to advance clinical trials targeting specific FTD pathologies. For this purpose, we developed a new ultrasensitive immunoassay to quantify acetylated tau at lysine 174 (AcTau174) in cerebrospinal fluid (CSF). In a sporadic cohort (n = 513), AcTau174 concentrations were higher in all dementia groups (FTLD-TDP, FTLD-Tau, Alzheimer’s disease (AD), mild cognitive impairment (MCI)-AD and dementia with Lewy bodies (DLB)) compared to controls. The largest increase was observed in the FTLD-TDP group, particularly patients with semantic variant primary progressive aphasia (svPPA) and GRN mutation carriers. Notably, AcTau174 discriminated FTLD-TDP from FTLD-Tau (area under the curve (AUC) = 0.83, 95% confidence interval (CI) = 0.75–0.91) and FTLD-TDP from controls (AUC = 0.95, 95% CI = 0.92–0.99) with high accuracy. This was replicated in independent, sporadic and genetic validation cohorts (164 patients and 24 controls), albeit with somewhat lower accuracy (FTLD-TDP versus FTLD-Tau; AUC range = 0.75–0.79) and wider CIs. Within the FTLD-TDP, AD and MCI-AD groups, higher AcTau174 concentrations were associated with a faster cognitive decline over time. In summary, CSF AcTau174 has great potential to discriminate FTLD-TDP from FTLD-Tau as a biomarker reflecting FTLD-TDP disease severity and progression.

3 December 2025 in Alzheimer's Research & Therapy
Verified
Journal Article
Open access
PDF file
MHMadison Honey
Madison Honey
IMIngrid S. van Maurik
Ingrid S. van Maurik
AHArgonde C. van Harten
Argonde C. van Harten
MGMariam Gouda
Mariam Gouda
MLMardou van Leeuwenstijn
Mardou van Leeuwenstijn
IVInge M. W. Verberk
Inge M. W. Verberk
Background: We aimed to develop individualized predictions for risk of developing any-cause dementia and Alzheimer’s disease (AD) dementia, in individuals with subjective cognitive decline (SCD) or mild cognitive impairment (MCI), using plasma phosphorylated-tau-181 (pTau181), phosphorylated-tau-217 (pTau217; in a subset), amyloid beta1-42/1–40 (Aβ42/40), glial fibrillary acidic protein (GFAP) and/or neurofilament light (NfL). Methods: From the Amsterdam Dementia Cohort we included 314 individuals with SCD (age 61 ± 9 years, n = 184 (59%) male, MMSE 29 ± 1) and 253 individuals with MCI (age 65 ± 7 years, n = 165 (65%) male, MMSE 27 ± 2), who had annual follow-up (median duration 2.4 years). Cox proportional hazards regression models were used to calculate probabilities for progression to dementia and were externally validated in MEMENTO and AIBL cohorts. Results: During follow-up 20 SCD and 99 MCI patients developed dementia. For MCI patients who progressed to any form of dementia, plasma GFAP contributed on top of age, sex, and MMSE score in the parsimonious individualized prognostic model (C-index = 0.69 [95%CI = 0.63; 0.76]). With AD-dementia as the outcome, GFAP and pTau181 were selected in the parsimonious model on top of the demographic variables (C-index = 0.71 [95%CI = 0.65; 0.76]). In the subset of 197 MCI individuals with pTau217 measurements, pTau217 was selected in the parsimonious model on top of the demographic variables (C-index = 0.75 [95%CI = 0.69; 0.79]). External validation demonstrated that the models are robust in a memory clinic setting. Conclusions: Our prediction models have utility for clinical practice to calculate progression probabilities for development of dementia in individual patients living with MCI over a 1-, 3- and 5-year time period.

23 December 2025 in Alzheimer's & Dementia
Verified
Journal Article
Open access
MHMadison Honey
Madison Honey
YHYanaika S. Hok‐A‐Hin
Yanaika S. Hok‐A‐Hin
ETElisabeth H Thijssen
Elisabeth H Thijssen
BWBabette van der Weijden
Babette van der Weijden
ESErik Stoops
Erik Stoops
CTCharlotte E. Teunissen
Charlotte E. Teunissen
Background: Post‐translational modifications of tau, such as acetylation, are emerging as key mechanisms in tau pathology. Tau acetylation at lysine 174 (AcTau174) is elevated in primary neurons with frontotemporal dementia (FTD)‐linked mutations and in early Alzheimer’s disease (AD) brain tissue. However, the utility of AcTau174 as a cerebrospinal fluid (CSF) biomarker across dementias is unknown, including in FTD, where AD‐type tau CSF biomarkers are typically not elevated. We investigated the diagnostic and prognostic potential of AcTau174 in a well‐characterized clinical cohort. Method: Using our in‐house developed Simoa assay, we measured AcTau174 in CSF samples from the Amsterdam Dementia Cohort (109 non‐neurodegenerative controls, 52 FTD, 145 AD, 97 mild cognitive impairment due to AD (MCI‐AD), and 31 dementia with Lewy bodies (DLB)). Result: AcTau174 levels were elevated in all dementia groups compared to controls, with a stepwise increase from controls to MCI‐AD (2.2‐fold) to AD dementia (3.5‐fold, Figure 1). The strongest increase compared to controls was observed in the FTD group, wherein AcTau174 distinguished FTD from controls with a high area under the curve (AUC) accuracy of 0.95 (95%CI:0.92;0.99), significantly outperforming CSF pTau181 (AUC=0.65, 95%CI:0.55;0.75) and CSF Tau (AUC=0.83, 95%CI:0.75;0.91). AcTau174 showed high accuracy for differentiating AD (AUC=0.98, 95%CI:0.96;0.99) and MCI‐AD (AUC=0.89, 95%CI:0.84;0.93) from controls (Figure 2). In FTD, AcTau174 correlated with MMSE (ρ=‐0.29, p =0.039), and in AD with the frontal assessment battery score (ρ=‐0.35, p =0.0001). In FTD, higher baseline CSF AcTau174 was associated with a faster rate of decline in MMSE over time (β=‐1.64, 95%CI:‐2.61;‐0.87, p =0.0014, Figure 3), which was not observed for CSF pTau181 or Tau. Higher baseline CSF AcTau174 also predicted faster MMSE decline within AD (β=‐1.66, 95%CI:‐2.44;‐0.90, p <0.0001) and MCI‐AD (β=‐0.67, 95%CI:‐1.09;‐0.27, p =0.002, Figure 3). Conclusion: CSF AcTau174 shows great diagnostic value across neurodegenerative dementias and is strongly associated with clinical progression. In FTD, where trials are limited by clinical heterogeneity and lack of fluid biomarkers, AcTau174 may aid in identifying patients at risk of rapid decline, supporting trial enrichment and more targeted intervention strategies. Its predictive capacity for MMSE decline highlights its potential as a progression biomarker, both for patient monitoring and therapeutic development.